Back to Results

Rosetta Genomics Ltd (ROSGQ)

Rosetta Genomics Ltd is a common stock listing on OTC Markets representing a healthcare company focused on genomic diagnostics. The company develops microRNA-based and other molecular tests used in cancer and pathology settings, including products for identifying the primary site of metastatic cancer, classifying kidney tumors, supporting thyroid nodule diagnosis, and testing for lung, bladder, prostate, colon, and melanoma-related conditions. Its portfolio also includes FISH-based assays such as UroVysion, ERG/PTEN, and ALK/ROS1, which are used alongside standard diagnostic procedures. Rosetta Genomics serves clinicians including oncologists, urologists, endocrinologists, and cytopathologists. The company has a license agreement with Max Planck Innovation GmbH covering proprietary microRNAs for diagnostics and research, and a collaboration with Meir Medical Center focused on a microRNA classifier for non-small cell lung cancer treatment research. Founded in 2000, the company is headquartered in Rehovot, Israel.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Analyst Price Target	Analyst Target Upside/Downside	Overall Financial Health	Dividend Yield	Market Cap
OTC-ROSG.Q	Not available	Not available	Not available	Good	0.0%	0.592 K

Smart Snapshot

Stock Overview

A fast read of the company and market metrics currently supported by the latest data.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Quality & Risk

Financial Health

Good

Valuation • Fair Value

Rosetta Genomics Ltd (OTC-ROSG.Q) Fair Value by Valuation Model

No usable valuation estimate is currently available for Rosetta Genomics Ltd (OTC-ROSG.Q); fair value and analyst target coverage statuses are shown explicitly below.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

No usable valuation estimate is currently available for Rosetta Genomics Ltd (OTC-ROSG.Q). Fair value and the analyst target remain visible as coverage-status fields and should not be read as valuation signals while unavailable.

Profitability • Growth

Profitability & Growth for Rosetta Genomics Ltd (OTC-ROSG.Q)

Review the profitability and growth indicators currently supported by the latest data.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Rosetta Genomics Ltd (OTC-ROSG.Q) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Rosetta Genomics Ltd (OTC-ROSG.Q)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Rosetta Genomics Ltd (OTC-ROSG.Q). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Rosetta Genomics Ltd (OTC-ROSG.Q)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Rosetta Genomics Ltd (OTC-ROSG.Q). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Rosetta Genomics Ltd (OTC-ROSG.Q) Stock Forecast & Technical Outlook

Review Rosetta Genomics Ltd (OTC-ROSG.Q) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy

Time frame: daily • daily

Sell

The daily technical read for Rosetta Genomics Ltd (OTC-ROSG.Q) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy

Time frame: weekly • weekly

Sell

The weekly technical read for Rosetta Genomics Ltd (OTC-ROSG.Q) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy

Time frame: monthly • monthly

Neutral

The monthly technical read for Rosetta Genomics Ltd (OTC-ROSG.Q) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Rosetta Genomics Ltd (OTC-ROSG.Q)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy

Consolidated analyst recommendation mix

Hold

Based on the available recommendation mix, Rosetta Genomics Ltd (OTC-ROSG.Q) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0

Hold 1

Sell 0

FAQ • Fast Investor Answers

Rosetta Genomics Ltd (OTC-ROSG.Q) Stock FAQ

Data-supported answers about Rosetta Genomics Ltd (OTC-ROSG.Q), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value

Not available

No reliable estimate from the currently supported inputs

Financial Health

Good

Current financial-health read

A reliable fair value estimate is not currently available for Rosetta Genomics Ltd (OTC-ROSG.Q). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

The current financial health read for Rosetta Genomics Ltd (OTC-ROSG.Q) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Rosetta Genomics Ltd (OTC-ROSG.Q).

The current market capitalization listed for Rosetta Genomics Ltd is 0.592 K.

The ticker symbol for Rosetta Genomics Ltd is OTC-ROSG.Q, and the stock is listed on OTC Markets.

Rosetta Genomics Ltd (OTC-ROSG.Q) is listed on OTC Markets.